Maria Demos

1.5k total citations
35 papers, 672 citations indexed

About

Maria Demos is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Maria Demos has authored 35 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 20 papers in Pathology and Forensic Medicine and 12 papers in Immunology. Recurrent topics in Maria Demos's work include Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (19 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Maria Demos is often cited by papers focused on Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (19 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Maria Demos collaborates with scholars based in United States, Israel and China. Maria Demos's co-authors include Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo, Amanda Kofides, Lian Xu, Kirsten Meid, Joshua Gustine, Manit Munshi and Nicholas Tsakmaklis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Maria Demos

32 papers receiving 668 citations

Peers

Maria Demos
Comparison fields: 5 of 33
  • Genetics 617
  • Pathology and Forensic Medicine 546
  • Immunology 270
  • Hematology 196
  • Oncology 87
Replace Amanda Kofides with:
Amanda Kofides United States
Nicholas Tsakmaklis United States
Manit Munshi United States
Jiaji G. Chen United States
Toni Dubeau United States
Fiona Bennett United Kingdom
Rebecca Auer United Kingdom
Roelandt F.J. Schop United States
Elisabeth Bertrand France
Alice Mohr United States
Amanda Kofides United States View profile →
Citations per field, relative to Maria Demos
Maria Demos · 1×
Citations per year, relative to Maria Demos
Maria Demos · 1×

Countries citing papers authored by Maria Demos

Since Specialization
Citations

This map shows the geographic impact of Maria Demos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Demos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Demos more than expected).

Fields of papers citing papers by Maria Demos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Demos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Demos. The network helps show where Maria Demos may publish in the future.

Co-authorship network of co-authors of Maria Demos

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Demos. A scholar is included among the top collaborators of Maria Demos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Demos. Maria Demos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
2021 ·Haematologica ·Joshua Gustine, Shayna Sarosiek, Catherine Flynn, Kirsten Meid, (unknown), Timothy P. White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo
9
2
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
2021 ·HemaSphere ·Amanda Kofides, Zachary R. Hunter, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Manit Munshi, Xia Liu, Maria Luisa Guerrera, (unknown), Timothy P. White, Catherine Flynn, Kirsten Meid, Christopher J. Patterson, Guang Yang, Andrew R. Branagan, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon, Joshua Gustine
16
3
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials
2020 ·HemaSphere ·Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Catherine Flynn, Maria Demos, Maria Luisa Guerrera, Cristina Jiménez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
11
4
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
2020 ·Blood Advances ·Xia Liu, (unknown), Manit Munshi, Zachary R. Hunter, Lian Xu, Amanda Kofides, Nickolas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, Gloria Chan, Cristina Jiménez, Christopher J. Patterson, Kirsten Meid, Andrew Keezer, Jorge J. Castillo, Steven P. Treon, Guang Yang
15
5
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia
2020 ·Leukemia & lymphoma ·Jorge J. Castillo, Gilad Itchaki, Joshua Gustine, Kirsten Meid, Catherine Flynn, Maria Demos, Maria Luisa Guerrera, Cristina Jiménez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
10
6
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
2020 ·Blood Advances ·Jorge J. Castillo, Kirsten Meid, Catherine Flynn, (unknown), Maria Demos, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Guang Yang, Zachary R. Hunter, Steven P. Treon
38
7
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
2019 ·Clinical Lymphoma Myeloma & Leukemia ·Joshua Gustine, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, (unknown), Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo
0
8
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
2019 ·British Journal of Haematology ·Jorge J. Castillo, Lian Xu, Joshua Gustine, Andrew Keezer, Kirsten Meid, Toni Dubeau, Xia Liu, Maria Demos, Amanda Kofides, Nicholas Tsakmaklis, Jiaji G. Chen, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher J. Patterson, Guang Yang, Zachary R. Hunter, Steven P. Treon
69
9
The BCR component SYK is activated by mutated MYD88 and the combined inhibition of SYK and BTK produces synthetic lethality in MYD88 driven B-cell lymphomas.
2019 ·Clinical Lymphoma Myeloma & Leukemia ·Manit Munshi, Xia Liu, (unknown), Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria Chan, Cristina Jiménez, Zachary R. Hunter, Christopher J. Patterson, Kirsten Meid, Andrew Keezer, Jorge J. Castillo, Steven P. Treon, Guang Yang
1
10
Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia
2019 ·American Journal of Hematology ·Jorge J. Castillo, Joshua Gustine, Andrew Keezer, Kirsten Meid, Catherine Flynn, Toni Dubeau, Gloria Chan, (unknown), Maria Demos, Maria Luisa Guerrera, Cristina Jiménez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
4
11
Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia
2018 ·Blood ·Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, Xia Liu, Christopher J. Patterson, Maria Luisa Guerrera, Manit Munshi, Guang Yang, Jiaji G. Chen, Cristina Jiménez, Gloria Chan, Joshua Gustine, Jorge J. Castillo, Steven P. Treon, Zachary R. Hunter
2
12
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
2018 ·Blood Advances ·Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Cristina Jiménez, Gloria Chan, (unknown), Xia Liu, Manit Munshi, Joshua Gustine, Kirsten Meid, Christopher J. Patterson, Guang Yang, Toni Dubeau, Mehmet Samur, Jorge J. Castillo, Kenneth C. Anderson, Nikhil C. Munshi, Steven P. Treon
60
13
Mutated MYD88 Homozygosity Is Increased in Previously Treated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure
2017 ·Blood ·Nickolas Tsakmaklis, Lian Xu, Robert Manning, Guang Yang, Xia Liu, (unknown), Maria Demos, Amanda Kofides, Gloria Chan, Maria Luisa Guerrera, Christopher J. Patterson, Jorge J. Castillo, Steven P. Treon, Zachary R. Hunter
2
14
MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia
2017 ·Blood ·Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Liu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, (unknown), Gloria Chan, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo
1
15
Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in Waldenstrom's Macroglobulinemia
2017 ·Blood ·Manit Munshi, Xia Liu, (unknown), Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria Chan, Zachary R. Hunter, Christopher J. Patterson, Joshua Gustine, Jorge J. Castillo, Steven P. Treon, Guang Yang
1
16
MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
2017 ·British Journal of Haematology ·Steven P. Treon, Joshua Gustine, Lian Xu, Robert Manning, Nicholas Tsakmaklis, Maria Demos, Kirsten Meid, Maria Luisa Guerrera, Manit Munshi, Gloria Chan, (unknown), Amanda Kofides, Christopher J. Patterson, Guang Yang, Xia Liu, Patricia Severns, Toni Dubeau, Zachary R. Hunter, Jorge J. Castillo
65
17
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
2017 ·Blood ·Lian Xu, Nicholas Tsakmaklis, Guang Yang, Jiaji G. Chen, Xia Liu, Maria Demos, Amanda Kofides, Christopher J. Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, M. Lia Palomba, Ranjana H. Advani, Jorge J. Castillo, Richard R. Furman, Zachary R. Hunter, Steven P. Treon
105
18
The Genomic Landscape of MYD88 Wild-Type WaldenströM's Macroglobulinemia Ischaracterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2
2017 ·Blood ·Zachary R. Hunter, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Lian Xu, Gloria Chan, (unknown), Manit Munshi, Xia Liu, Joshua Gustine, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo, Guang Yang, Steven P. Treon
1
19
Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia
2016 ·Blood ·Steven P. Treon, Nicholas Tsakmaklis, Kirsten Meid, Guang Yang, Jiaji G. Chen, Xia Liu, Jie Chen, Maria Demos, Christopher J. Patterson, Toni Dubeau, Joshua Gustine, Jorge J. Castillo, Ranjana H. Advani, Maria Lia Palomba, Lian Xu, Zachary R. Hunter
6
20
Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib
2016 ·Blood ·Jiaji G. Chen, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J. Patterson, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon, Guang Yang
3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amanda Kofides Breakdown of academic impact, for papers by Nicholas Tsakmaklis Breakdown of academic impact, for papers by Manit Munshi Breakdown of academic impact, for papers by Jiaji G. Chen Breakdown of academic impact, for papers by Toni Dubeau Breakdown of academic impact, for papers by Fiona Bennett Breakdown of academic impact, for papers by Rebecca Auer Breakdown of academic impact, for papers by Roelandt F.J. Schop Breakdown of academic impact, for papers by Elisabeth Bertrand Breakdown of academic impact, for papers by Alice Mohr
Rankless by CCL
2026